News
VRTX
417.32
-0.27%
-1.14
bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates
NASDAQ · 21h ago
Wall Street Lunch: Florida Bans Social Media For Under 14
Florida signs bill requiring parental consent for minors to create social media accounts. McDonald's will start selling Krispy Kreme doughnuts this year. Maersk chartered vessel that brought down Baltimore bridge. UPS looks to return to growth with plans to sell doughnuts nationwide.
Seeking Alpha · 1d ago
Biotech Roundtable: Is CRISPR all its cracked up to be?
CRISPR gene editing technology has been heralded as a revolutionary breakthrough in drug development. The FDA approved the first CRISPR product for the US market last fall. Is CRisPR overhyped? Which companies are most attractive right now in the space? Seeking Alpha biotech analysts Stephen Ayers and Edmund Ingham weigh in.
Seeking Alpha · 1d ago
Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available for CASGEvY in approved countries. Private insurers are showing interest in covering the treatment, providing further support for its commercial launch. I continue to hold a buy rating on CrisprTherapeutics.
Seeking Alpha · 2d ago
Vertex (VRTX) Continues to Diversify Beyond CF Franchise
NASDAQ · 3d ago
Weekly Report: what happened at VRTX last week (0318-0322)?
Weekly Report · 3d ago
Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development
NASDAQ · 5d ago
Analyst Issues Sell Rating for Vertex Pharmaceuticals Amid Intensifying Drug Market Competition
TipRanks · 6d ago
Vertex Gets FDA Nod Of IND For VX-407 For Autosomal Dominant Polycystic Kidney Disease
NASDAQ · 03/21 12:45
Vertex expands kidney disease research as FDA clears clinical trial
Seeking Alpha · 03/21 12:28
Vertex Gets FDA OK to Study VX-407 in Genetic Kidney Disease
Vertex Pharmaceuticals to study its drug candidate in certain patients with the most common inherited kidney disease. 250,000 people in the U.S. And Europe suffer from autosomal dominant polycystic kidney disease, or ADPKD. Boston drugmaker plans to launch a Phase 1 study in healthy volunteers this month.
Dow Jones · 03/21 12:18
Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Seeking Alpha · 03/21 04:00
bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up
NASDAQ · 03/19 11:44
Bluebird secures up to $175M financing amid gene therapy launches
Healthcare Bluebird secures up to $175M financing amid gene therapy launches. The biotech company said the transaction will help strengthen its balance sheet as it commercializes its gene therapies. The FDA approved bluebird's sickle cell disease gene therapy in December. Bluebird bio said it has secured $175 million in debt financing with Hercules Capital.
Seeking Alpha · 03/18 15:02
IWY, ISRG, SBUX, VRTX: Large Outflows Detected at ETF
NASDAQ · 03/18 14:58
VRTX September 20th Options Begin Trading
NASDAQ · 03/18 14:49
Weekly Report: what happened at VRTX last week (0311-0315)?
Weekly Report · 03/18 09:26
2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
Vertex Pharmaceuticals and HCA Healthcare are two healthcare stocks worth investing in and holding on to. The drugmaker is developing new treatments for cystic fibrosis. The hospital chain has a strong position in its industry. The company has been able to increase its market share over the long run.
The Motley Fool · 03/17 13:50
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
Three Motley Fool contributors have identified unstoppable stocks they think you can buy now. Eli Lilly, Novo Nordisk and Vertex Pharmaceuticals are among them. The drugmaker has been hit with regulatory setbacks but is still a no-brainer stock to buy. The companies also have promising growth prospects in the future.
The Motley Fool · 03/17 13:00
Forget Tesla, Buy This Magnificent Healthcare Stock Instead
Vertex Pharmaceuticals is an exciting healthcare company to invest in. The company has grown its revenue from $6.2 billion in 2020 to $9.9 billion this past year. Vertex has a strong growth trajectory and is on the cusp of even more growth. The stock of the company is trading at less than 30 times its expected future earnings.
The Motley Fool · 03/17 12:54
More
Webull provides a variety of real-time VRTX stock news. You can receive the latest news about Vertex Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.